Catalent, a New Jersey-based biotech firm with a facility on Madison’s far west side, has announced it plans to hold an initial public offering that could raise as much as $100 million. The company, which is owned by The Blackstone Group, filed a statement with the Securities and Exchange Commission late last week and said it intends to use proceeds from the IPO to repay debt. Catalent makes drug-delivery technologies for pharmaceutical companies and employs 8,500 people in 30 facilities around the world.
Catalent files for IPO
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
